Opioid class REMS will not delay new drug approvals, FDA says
01 June 2009
Sue Sutter
Please Login to read the full article.
01 June 2009
Sue Sutter
Ongoing deliberations over a single risk evaluation and mitigation strategy (REMS) for long-acting and sustained-release opioids will not block approval of new drugs within the class, US FDA office of new drugs director Dr John Jenkins said.
Speaking to reporters after a two-day...
Please Login to read the full article.
RELATED CONTENT
NEWS
- BDSI CEO: Shared fentanyl REMS puts Onsolis on level playing field
- PharmacoFore secures $10M Series B to advance "next generation" abuse resistant opioids, plus propofol alternative
- Acura investors euphoric over US FDA OK of oxycodone painkiller
- Janssen wins US FDA nod for chronic pain drug Nucynta ER
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
